This book covers pharmacological activity and the role of the medications used for the medical management of obesity. The chapters provide information on the prevalence of obesity, basic principles of obesity management, a brief history of anti-obesity medications (AOMs), and discontinuation of AOMs due to their safety concerns. Further chapters include information on currently approved AOMs for obesity management by healthcare regulatory authorities including their effect on weight loss and other important clinical parameters, short-term and long-term use of AOMs, medications for genetic obesity, and the use of AOMs in obesity with associated co-morbidities as per their safety considerations and contraindications. A separate chapter is on drugs that are either under a clinical trial phase or awaiting approval.
The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the external editor. The editor of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that the auto-summaries consist of original sentences, but are not representative of the original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here and that machine-generated books are still at an experimental stage
The book is relevant for healthcare and pharmaceutical professionals.
Chapter 1 Introduction to obesity and Anti-Obesity Medications.
Chapter 2 Orlistat: A Gastrointestinal Lipase Inhibitor.
Chapter 3 Fixed Combination Anti-Obesity Medications.
Chapter 4 Role of Incretin Mimetics in the Management of Obesity.
Chapter 5 Anti-Obesity Medications for Monogenic Syndromic Obesity.
Chapter 6 Future Perspectives in the Management of Obesity.
Chapter 7 Person-Centered Approach and Challenges in the Management of Obesity.
Dr. Shilpa Chugh Garcha (MBBS, MD Pharmacology) completed her graduation in medicine from Dayanand Medical College and Hospital, Ludhiana, India; postgraduation from Government Medical College, Patiala, India. She has worked as an assistant professor of pharmacology at SGT Medical College, Haryana, India. Dr. Shilpa was also part of the medical affairs team of Novo Nordisk India, wherein her primary work was medico-marketing of newer diabetes therapies. She worked at Baxter India as a clinical marketing advisor for IV fluids and parenteral nutrition. Dr. Shilpa also worked as a senior manager, medical affairs, at 1mg.com and was responsible for editing and reviewing drug-related medical information for patients.
Dr. Sanjay Kalra (MBBS, MD, DM) completed his graduation in medicine from Punjab University, Chandigarh, India; post-graduation in medicine from Maharshi Dayanand University, Rohtak, India; doctorate of medicine in endocrinology from All India Institute of Medical Sciences, New Delhi, India. He is working as an endocrinologist at Bharti Hospital, Karnal, India. Dr. Sanjay is currently the Treasurer, International Society of Endocrinology, and Vice President, South Asian Obesity Forum. Dr. Sanjay was president of the South Asian Federation of Endocrine Societies (SAFES); chairperson of the Education Working Group, the International Society of Endocrinology, and president of the Indian Professional Association of Transgender Health. In the past, he was also the president of the Endocrine Society of India. He was part of the editorial board of Diabetes Therapy, European Endocrinology, and the Indian Journal of Endocrinology and Metabolism. Dr. Sanjay works to spread endocrine and diabetes awareness across the world.
Lisainfo e-raamatute kohta